Spotlight on tNOX: A tumor-selective target for cancer therapies

Drug News and Perspectives

Volumn 19, Issue 4, 2006, Pages 223-225

  Davies, Shelley L ^a   Bozzo, Jordi ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 CHLOROPHENYL) 3 (4 METHYLPHENYLSULFONYL)UREA; ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; ASCORBIC ACID; BTS 2; CAPSAICIN; CELECOXIB; CELL SURFACE PROTEIN; CYCLOOXYGENASE 2 INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIGALLOCATECHIN GALLATE; GRAPE EXTRACT; HERBACEOUS AGENT; IBUPROFEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 12.1; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENOXODIOL; PIROXICAM; PLANT EXTRACT; PROTEIN INHIBITOR; ROFECOXIB; TUMOR ASSOCIATED NOX; UNCLASSIFIED DRUG;

ADENOCARCINOMA; BLADDER CANCER; CANCER RECURRENCE; CANCER THERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; OVARY CANCER; PERITONEUM CANCER; PROTEIN TARGETING; SHORT SURVEY; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA; UTERINE TUBE CARCINOMA; VAGINA CARCINOMA; VULVA CARCINOMA;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; NADH, NADPH OXIDOREDUCTASES; NEOPLASMS;

EID: 33748951935     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2006.19.4.1007077     Document Type: Short Survey

References (19)

1. Sedlak, D., Moore, D.M. and Moore, D.J. A drug-unresponsive and protease-resistant cNOX protein from human sera. Arch Biochem Biophys 2001, 386: 106-16.
2. Kelker, M., Kim, C., Chueh, P.J., Guimont, R., Morre, D.M. and Morre, D.J. Cancer isoform of a tumor-associated cell surface NADH oxidase (tNOX) has properties of a prion. Biochemistry 2001, 40: 7351-4.
3. Morre, D.J., Sun, E., Geilen, C. et al. Capsaicin inhibits plasma membrane NADH oxidase and growth of human and mouse melanoma lines. Eur J Cancer 1996, 32A: 1995-2003.
4. Morre, D.J., Wu, L.Y. and Morre, D.M. The antitumor sulfonylurea N-(4-Methylphenylsulfonyl)-N′-(4-Chlorophenyl) urea (LY181984) inhibits NADH oxidase activity of HeLa plasma membranes. Biochim Biophys Acta 1995, 1240: 11-7.
5. Morre, D.J. and Morre, D.M. Cell surface NADH oxidases (ECTO-NOX proteins) with roles in cancer, cellular time-keeping, growth, aging and neurodegenerative diseases. Free Radic Res 2003, 37: 795-808.
6. Morre, D.J., Chueh, P.J., Pletcher, J., Tang, X., Wu, L.Y. and Morre, D.M. Biochemical basis for the biological clock. Biochemistry 2002, 41: 11941-5.
7. Yagiz, K., Morre, D.J. and Morre, D.M. Transgenic mouse line overexpressing the cancer-specific tNOX protein has an enhanced growth and acquired drug-response phenotype. J Nutr Biochem 2006, Advance Publication.
8. Cho, N., Chueh, P.J., Kim, C., Caldwell, S., Morre, D.M. and Morre, D.J. Monoclonal antibody to a cancer-specific and drug-responsive hydroquinone (NADH) oxidase from the sera of cancer patients. Cancer Immunol Immunother 2002, 51: 121-9.
9. Wang, S., Morre, D.M. and Morre, D.J. Sera from cancer patients contain two oscillating ECTO-NOX activities with different period lengths. Cancer Lett 2003, 190: 135-41.
10. Morre, D.J. and Morre, D.M. tNOX, an alternative target to COX-2 to explain the anticancer activities of non-steroidal anti-inflammatory drugs (NSAIDS). Mol Cell Biochem 2006, 283: 159-67.
11. Morre, D.J., Morre, D.M., Sun, H., Cooper, R., Chang, J. and Janle, E.M. Tea catechin synergies in inhibition of cancer cell proliferation and of a cancer specific cell surface oxidase (ECTO-NOX). Pharmacol Toxicol 2003, 92: 234-41.
12. Erlotinib and green tea extract (Polyphenon® E) in preventing cancer recurrence in former smokers who have undergone surgery for bladder cancer (NCT00088946). ClinicalTrials.gov Web Site 2006, February 23.
13. Green tea extract for treatment of chronic lymphocytic leukemia (NCT00166335). ClinicalTrials.gov Web Site 2005, December 8.
14. Axanova, L., Morre, D.J. and Morre, D.M. Growth of LNCaP cells in monoculture and coculture with osteoblasts and response to tNOX inhibitors. Cancer Lett 2005, 225: 35-40.
15. http://www.marshalledwardsinc.com/.
16. Phenoxodiol in treating patients with refractory solid tumors (NCT00022295). ClinicalTrials.gov Web Site 2005, December 8.
17. Encio, I., Morre, D.J., Villar, R., Gil, M.J. and Martinez-Merino, V. Benzo[b]Thiophenesulphonamide 1,1-Dioxide derivatives inhibit tNOX activity in a redox state-dependent manner. Br J Cancer 2005, 92: 690-5.
18. Morre, D.J., Kim, C., Paulik, M., Morre, D.M. and Faulk, W.P. Is the drug-responsive NADH oxidase of the cancer cell plasma membrane a molecular target for Adriamycin? J Bioenerg Biomembr 1997, 29: 269-80.
19. Morre, D.M. and Morre, D.J. Anticancer activity of grape and grape skin extracts alone and combined with green tea infusions. Cancer Lett 2005, Advance Publication.